ReviewDrugs2008
Steroid-refractory severe ulcerative colitis: what are the available treatment options?
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis.Irish journal of medical science · 2018Pooled it
- Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis.Digestive diseases and sciences · 2015Pooled it
- Article
- Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.AAPS PharmSciTech · 2021Review
- Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis.Alimentary pharmacology & therapeutics · 2012Article
- Mesalamine in the treatment and maintenance of remission of ulcerative colitis.Expert review of clinical pharmacology · 2012Review
- Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Clinical pharmacology : advances and applications · 2012Article
- Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2011Article
- Infliximab to treat severe ulcerative colitis.World journal of gastroenterology · 2009Article
- Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Clinical and experimental gastroenterology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent or surgery. Ciclosporin has proven its efficacy in a number of controlled trials in this setting and is characterized by high early response rates. Patients who respond to ciclosporin and avoid colectomy are more likely to retain their colon if they bridge to immunomodulators in the medium term. Infliximab has also demonstrated efficacy in reducing early colectomy rates and longer term data are awaited. Other agents, such as tacrolimus and basiliximab, and leukocytapheresis, have been studied in small trials and may be alternative options. Key issues remain as to what should be first- and second-line therapies, when surgery should be undertaken, and the risk of switching between immunosuppressants in these critical patients.
Indexed as
Identifiers
18547130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.